Cargando…

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly

Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss their phenotype and acquire mesenchymal traits, including increased migratory and invasive capacities. EMT is involved in physiological processes, such as embryogenesis and wound healing, and in pathological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil, Joan, Jordà, Mireia, Soldevila, Berta, Puig-Domingo, Manel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006574/ https://www.ncbi.nlm.nih.gov/pubmed/33790868 http://dx.doi.org/10.3389/fendo.2021.646210

Ejemplares similares

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response
por: Gil, Joan, et al.
Publicado: (2022)

Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective
por: Nista, Federica, et al.
Publicado: (2021)

Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors
por: Gil, Joan, et al.
Publicado: (2023)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
por: Marques-Pamies, Montserrat, et al.
Publicado: (2023)

Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer
por: Dharan, Shalini Sree, et al.
Publicado: (2017)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)
por: Brunetti, Alessandro, et al.
Publicado: (2022)

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
por: Biagetti, Betina, et al.
Publicado: (2022)

Insulin Resistance in Patients With Acromegaly
por: Vila, Greisa, et al.
Publicado: (2019)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
por: Prencipe, N., et al.
Publicado: (2020)

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Wildemberg, Luiz Eduardo, et al.
Publicado: (2021)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
por: van Albada, Mirjam E., et al.
Publicado: (2022)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

The Endothelium in Acromegaly
por: Maffei, Pietro, et al.
Publicado: (2019)

The acromegaly lipodystrophy
por: Freda, Pamela U.
Publicado: (2022)

Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2019)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
por: Pichler, Robert, et al.
Publicado: (2021)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Colonic Cancer and Acromegaly
por: Dworakowska, Dorota, et al.
Publicado: (2019)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia
por: Xu, Deqiang, et al.
Publicado: (2019)

Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer
por: Bhattacharya, Debasmita, et al.
Publicado: (2019)

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
por: Carmichael, John D., et al.
Publicado: (2014)

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
por: Geer, Eliza B., et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2hdee23hre76osv2a2ekgtudnj